Effect of irradiation on transforming growth factor-β secretion by malignant glioma cells

Journal of Neuro-Oncology

Volumn 33, Issue 3, 1997, Pages 195-200

  Satoh, Eiji ^a   Naganuma, Hirofumi ^a   Sasaki, Atsushi ^a   Nagasaka, Mitsuyasu ^a   Ogata, Hitoshi ^a   Nukui, Hideaki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Glioblastoma; Irradiation; Malignant glioma; Transforming growth factor

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CULTURE MEDIUM; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PROTEIN SECRETION; RADIATION DOSE; TUMOR GROWTH;

ANIMALS; CULTURE MEDIA, SERUM-FREE; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNE TOLERANCE; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0030902396     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005791621265     Document Type: Article

References (35)

1. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A: Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2. J Immunol 143: 3222-3229, 1989
2. Naganuma H, Sasaki A, Satoh E, Sakihama T, Tasaka K, Nukui H: Improved bioassay for detection of transforming growth factor-β1 and β2 in malignant gliomas. Neurol Med Chir (Tokyo) 34: 143-149, 1994
3. Wrann M, Bodmer S, de Martin R, Siepel C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO J 6: 1633-1636, 1987
4. Schwyzer M, Fontana A: Partial purification and biochemical characterization of a T cell suppressor factor produced by human glioblastoma cells. J Immunol 134: 1003-1009, 1985
5. Wahl SM, Allen JB, Wong HL, Dougherty SF, Ellingsworth LR: Antagonistic and agonistic effects of transforming growth factor-β and IL-1 in rheumatoid synovium. J Immunol 145: 2514-2519, 1990
6. Ignotz RA, Masague J: Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261: 4337-4345, 1986
7. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS: Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes. J Immunol 137: 3855-3860, 1986
8. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS: Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163: 1037-1050, 1986
9. Espevik T, Figari IS, Shlaby MR, Lackides GA, Levis GD, Shepard HM, Palladino MA: Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J Exp Med 166: 571-576, 1987
10. Espevik T, Figari IS, Ranges GE, Palladino MA: Transforming growth factor-β1 (TGF-β1) and recombinant human tumor necrosis factor-α reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-β1 and TGF-β2, and recombinant human TGF-β1. J Immunol 140: 2312-2316, 1988
11. Rook AH, Kehrl JH, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS: Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916-3920, 1986
12. Ranges GE, Figari IS, Espevik T, Palladino MA: Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 166: 991-998, 1987
13. Kasid A, Bell GI, Director EP: Effects of transforming growth factor-β on human lymphokine-activated killer cell precursors: autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 141: 690-698, 1988
14. Naganuma H, Sasaki A, Satoh E, Tasaka K, Nukui H: Inhibition of tumor necrosis factor-α and β secretion from lymphokine activated killer cells by transforming growth factor-β. Jpn J Cancer Res 85: 952-957, 1994
15. Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K, Yamamoto S, Kageyama N, Handa H, Mogami H, Nishimoto A, Uozumi T, Matsutani M, Nomura K: Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 64: 53-57, 1986
16. Walker MD, Alexander E, Hunt WE, Maccarty C, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333-343, 1978
17. Holladay FP, Wood GW: Generation of cellular immune responses against a glioma-associated antigens. J Neuroimmunol 44: 27-32, 1993
18. Holladay FP, Choudhuri R, Heitz T, Wood GW: Generation of cytotoxic immune responses during the progression of a rat glioma. J Neurosurg 80: 90-96, 1994
19. Miyatake S, Kikuchi H, Iwasaki K, Yamashita J, Li ZY, Namba Y, Hanaoka M: Specific cytotoxic activity of T lymphocyte clones derived from a patient with gliosarcoma. J Neurosurg 69: 751-759, 1988
20. Moriyama T, Suzuki G, Nakao I, Aizawa S, Okumura K, Nishimura T, Takaku F: Induction of anomalous killing activity from antigen-specific CTL clones by adding high doses of human recombinant interleukin 2. Cell Immunol 111: 482-491, 1988
21. Bristol LA, Ruscetti FW, Brody DT, Durum SK: IL-1α induces expression of active transforming growth factor-β in nonproliferating T cells via a post-transcriptional mechanism. J Immunol 145: 410-4114, 1990
22. Brown PD, Wakefield LM, Levinson AD, Sporn MB: Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Growth Factors 3: 35-43, 1990
23. Anscher MS, Crocker IR, Jirtle RL: Transforming growth factor-β1 expression in irradiated liver. Radiat Res 122: 77-85, 1990
24. Finkelstein JN, Johnston CJ, Baggs R, Rubin P: Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiat Oncol Biol Phys 28: 621-631, 1994
25. Barcellos-Hoff MH: Radiation-induced transforming growth factor beta and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res 53: 3880-3886, 1993
26. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA: Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 93: 892-899, 1994
27. Brooks WH, Caldwell HD, Mortara RH: Immune responses in patients with gliomas. Surg Neurol 2: 419-423, 1974
28. Mahaley MS, Brooks WH, Roszaman TL, Binger DD, Dudka L, Richardson S: Immunobiology of primary intracranial tumors. Part I: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg 46: 467-476, 1977
29. Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2. J Neurosurg 71: 211-217, 1989
30. Maxwell MB, Galanopoulos T, Neville-Golden J, Antoniades HN: Effects of expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 76: 799-804, 1992
31. Miescher S, Whiteside TL, Carrel S: Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136: 1899-1907, 1986
32. Muul LM, Director EP, Hyatt CL, Rosenberg SA: Large scale production of human lymphokine activated killer cells for use in adoptive immuntherapy. J Immunol Methods 88: 265-275, 1986
33. Nitta T, Sato K, Yagita N, Okumura K, Ishii S: Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368-371, 1990
34. Yoshida S, Tanaka R, Takai N, Ono K: Local administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to the patients with malignant brain tumor. Cancer Res 48: 5011-5016, 1988
35. Hurd SD, Johnson MD, Forbes JT, Carty-Dugger TL, Arteaga CL: Neutralizing TGF-β antibodies increase natural killer (NK) cell activity and inhibit human breast cancer cell tumorigenicity in athymic mice. Proceedings of American Association of Cancer Research 33: 80, 1992